Trial Profile

Trial to evaluate the administration of IDOR-1134-2831 vaccine in healthy participants

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IDO-090 (Primary)
Indications Clostridium difficile infections
Focus Adverse reactions; First in man
Sponsors Idorsia Pharmaceuticals

Most Recent Events

15 Jan 2025 According to Idorsia Pharmaceuticals media release, results from this study expected in Q2 2025.
25 Jul 2024 According to Idorsia Pharmaceuticals media release, first healthy participant entered Phase 1 program for Idorsias first synthetic glycan vaccine, targeting Clostridium difficile infection.
25 Jul 2024 Status changed from planning to recruiting as per Idorsia Pharmaceuticals media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com